(Q51345124)

4 April 2018

title

Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c <7%. (English)

1 reference

4 April 2018

1 reference

H Maeda

1

1 reference

4 April 2018

A Kubota

2

1 reference

4 April 2018

A Kanamori

3

1 reference

4 April 2018

Y Tanaka

4

1 reference

4 April 2018

Y Terauchi

5

1 reference

4 April 2018

I Matsuba

6

1 reference

4 April 2018

ASSET-K Study Group

7

1 reference

4 April 2018

publication date

4 February 2013

1 reference

4 April 2018

Journal of Endocrinological Investigation

published in

1 reference

4 April 2018

volume

36

1 reference

4 April 2018

page(s)

568-573

1 reference

4 April 2018

issue

8

1 reference

4 April 2018

https://scigraph.springernature.com/pub.10.3275/8819

exact match

0 references

cites work

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients

1 reference

12 December 2020

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

1 reference

12 December 2020

Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients

1 reference

12 December 2020

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance

1 reference

12 December 2020

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

12 December 2020

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

1 reference

12 December 2020

Standards of medical care in diabetes--2011.

1 reference

12 December 2020

The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes

1 reference

12 December 2020

Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels

1 reference

12 December 2020

Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan

1 reference

12 December 2020

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

1 reference

12 December 2020

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

1 reference

12 December 2020

Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients

1 reference

12 December 2020

Intestinal Factors in the Control of Insulin Secretion

1 reference

12 December 2020

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

1 reference

12 December 2020

Heterogeneous relationship of early insulin response and fasting insulin level with development of non-insulin-dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity.

1 reference

12 December 2020

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial

1 reference

12 December 2020

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

1 reference

12 December 2020

Food intake patterns and 25-year mortality from coronary heart disease: cross-cultural correlations in the Seven Countries Study. The Seven Countries Study Research Group.

1 reference

12 December 2020

Identifiers

DOI

10.3275/8819

1 reference

4 April 2018

Dimensions Publication ID

0 references

1 reference

4 April 2018